Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19102


Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation


Inclusion Criteria: - Capable of and willing to provide informed consent - Evidence of HIV infection (either HIV-seropositive, CD4+ T-cell count of ≤350/mm3 or other clinically accepted indicator) - An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size, or a recent history of unintentional weight loss of 10% from the subjects baseline - Weight losses was clinically associated with AIDS-related wasting and not related to any other disease process - Women of childbearing potential had to agree to use effective contraception for the duration of the study and for two weeks after the last dose - Clinical laboratory values had to be within normal limits or out-of-range limits must be designated as not clinically significant (some exceptions per protocol) - Able to read and write in the study related documents translated into the primary local language - Capable of and willing to return to the clinic regularly for study visits - Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry - Capable of completing a 3-day food intake diary with instruction - Willing to abstain from any illegal or recreational drug substances for the duration of the trial - Willing to abstain from taking any other medications or substances known to affect appetite or weight gain (eg, steroids [other than those inhaled for treatment of asthmatic conditions], nutritional supplements [other than vitamins or minerals], dronabinol, recombinant human growth hormone, etc.) Exclusion Criteria: - Weight loss due to factors other than AIDS-related wasting - Enrollment in any other clinical trial - Lack of access to regular meals - Women of childbearing potential could not be pregnant or nursing - Clinically severe depression evidenced by a baseline score of 17 or more on the Hamilton Depression Rating Scale (GRID-HAMD-17) - Recent evidence of or history of significant psychiatric illness that may have compromised the subject's ability to comply with the study requirements - Intractable or frequent vomiting that regularly interfered with eating - Clinically significant diarrhea that would have interfered with absorption of foods or medications - Clinically significant oral lesions or dental conditions that would have interfered with eating a regular diet - History or evidence of thromboembolic events or any first degree relative with a history of thromboembolic events - Active AIDS-defining illness or other clinically significant or uncontrolled medical problems - Current evidence of or history of diabetes mellitus or hypoadrenalism - Systemic treatment with glucocorticoids within the 12 months prior to study entry



Primary Contact:

Principal Investigator
Jan Fourie, MD
58 Ann Street, Dundee, KZ-Natal 3000, S. Africa

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19102
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.